within Pharmacolibrary.Drugs.ATC.S;

model S01GA55
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.030000000000000002,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01GA55</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Phenylephrine is an alpha-1 adrenergic receptor agonist commonly used as a mydriatic (to dilate the pupil) and decongestant, often in combination with other agents for ophthalmic use. The ATC code S01GA55 corresponds to combinations containing phenylephrine for ophthalmic application. It is approved and still used in clinical ophthalmology.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies were found specifically for ophthalmic phenylephrine-containing combinations (ATC S01GA55) in humans. Thus, pharmacokinetic parameters are estimated based on known properties of topical phenylephrine in adults.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Anderson, BJ (2015). Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. <i>European journal of clinical pharmacology</i> 71(8) 931–938. DOI:<a href=\"https://doi.org/10.1007/s00228-015-1876-1\">10.1007/s00228-015-1876-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26022219/\">https://pubmed.ncbi.nlm.nih.gov/26022219</a></p></li><li><p>Doughty, MJ, &amp; Lyle, WM (1992). A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation. <i>Optometry and vision science : official publication of the American Academy of Optometry</i> 69(5) 358–368. DOI:<a href=\"https://doi.org/10.1097/00006324-199205000-00005\">10.1097/00006324-199205000-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1350669/\">https://pubmed.ncbi.nlm.nih.gov/1350669</a></p></li><li><p>Seliniotaki, AK, et al., &amp; Mataftsi, A (2022). Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial. <i>Trials</i> 23(1) 322–None. DOI:<a href=\"https://doi.org/10.1186/s13063-022-06243-7\">10.1186/s13063-022-06243-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35428316/\">https://pubmed.ncbi.nlm.nih.gov/35428316</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01GA55;
